REsearch on BrEast Cancer Induced Chronic Conditions Supported by Causal Analysis of Multi-source Data

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

REBECCA-1 is an observational study. Clinical research is undergoing a revolutionary change. The use of electronic patient records (EHR), digital registers, smartphones etc will create real-world data (RWD) that provides great opportunities for advancing clinical research, but so far this opportunity has been little exploited. The REBECCA -1 study will observe and monitor fatigue in breast cancer survivors. Investigators will use self reported questionnaires (PROM-data), blood tests and objective regulations like the REBECCCA -1 smart watch that will register amount of steps every day, leaving the house, visiting friends, cafes etc. There will be three observational arms; 1.high fatigue, 2. low fatigue and 3. a healthy control arm. After the patients have finished their treatment, they will receive the REBECCA smart watch, a REBECCA app on the smart phone and a REBECCA plus device on their computer, The next offend are also invited to report their evaluation through the same apps. The observational time will be 1 year and comparison between the subjective PROM data , the objective REBECCA watch and the biological samples will be obtained.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 19
Maximum Age: 80
Healthy Volunteers: t
View:

• Breast cancer patients with histologically detectable M0 breast cancer (stage 0-III) who require neoadjuvant or adjuvant endocrine, chemo and / or radiation therapy at least and no more than 3 months before initiation of study.

• Female breast cancer patients between 19 and 80 years of age.

• Patients who have increased their life expectancy beyond the first 3 months after starting treatment.

• Patients who have the ability to understand the protocol and can participate in the follow-up plan.

• Patients who have an absence of psychological, familial, sociological or geographical condition that potentially impedes compliance with the study protocol and follow-up plan.

Locations
Other Locations
Norway
Helse Stavanger HF
RECRUITING
Stavanger
Contact Information
Primary
Tone Hoel Lende, PhD
leth@SUS.no
47861295
Backup
Håvard Søiland, PhD
hsoiland@gmail.com
45636028
Time Frame
Start Date: 2022-06-15
Estimated Completion Date: 2028-06-15
Participants
Target number of participants: 150
Treatments
Mild Cancer Related Fatigue
After treatment(6 months from inclusion) is ended a fVAS \< 50
Cancer related Fatigue
After treatment (6 months from inclusion) with fVAS ≥ 50 mm or a rise of fVAS of ≥ 25 mm.
Healthy control
Healthy women matches with age~1. 50-70: women attending the mammography screening~2. 19-50: invitation in newspaper, flyers and posters
Related Therapeutic Areas
Sponsors
Leads: Helse Stavanger HF

This content was sourced from clinicaltrials.gov